Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lacy Boyd

Physician Assistant, Medical Paducah, KY Physician Assistant

NPI 1194951418 CMS profile 11216970

2721 W Park Dr, Paducah, KY 42001

Open in the dashboard

General payments

$3,910

204 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lacy Boyd of Paducah, KY is reported in the CMS Open Payments database as having received $3,910 across 204 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,170 59
2024 General $720 39
2023 General $893 34
2022 General $593 35
2021 General $535 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lacy Boyd
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Lacy Boyd were reported at $1,170. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Lacy Boyd Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $535 $156 $41–$563 $132
2022 $593 $185 $55–$649 $149
2023 $893 $199 $58–$717 $160
2024 $720 $206 $62–$740 $164
2025 $1,170 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $892 44 payments
  2. Sun Pharmaceutical Industries Inc. $496 19 payments
  3. Novartis Pharmaceuticals Corporation $450 24 payments
  4. Regeneron Healthcare Solutions, Inc. $403 22 payments
  5. AbbVie, Inc. $279 19 payments
  6. E.R. Squibb & Sons, L.L.C. $226 12 payments
  7. UCB, Inc. $210 11 payments
  8. Amgen Inc. $196 10 payments
  9. Arcutis Biotherapeutics, Inc. $179 7 payments
  10. LEO Pharma Inc. $141 8 payments
  11. Other $436 28 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,496 199 payments
  2. Education $414 5 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $825 40 payments
  2. DUPIXENT Inflammation And Immunology $297 17 payments
  3. BLU-U $233 11 payments
  4. SOTYKTU $226 12 payments
  5. COSENTYX $201 13 payments
  6. Otezla $196 10 payments
  7. Bimzelx $184 9 payments
  8. ILUMYA $173 8 payments
  9. RINVOQ $134 10 payments
  10. DUPIXENT Immunology $113 5 payments
  11. Other $1,457 87 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

789

Median for Physician Assistant: 241

Drug cost

$110,018

Median for Physician Assistant: $4,110

Branded share of claims

8.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 22 $84,153
Fluorouracil Generic 96 $7,484
Pimecrolimus Generic 28 $3,925
Betamethasone Dipropionate Generic 67 $2,483
Ketoconazole Generic 112 $2,250
Clobetasol Propionate Generic 40 $1,532
Metronidazole Generic 25 $1,446
Mupirocin Generic 172 $1,063
Tacrolimus Generic 14 $1,055
Tretinoin Generic 15 $962

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$144,613

Of which drugs: $15,733

Medicare patients

799

Average age 74

Services billed

3,268

504 women, 295 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 28%
Ischemic heart disease 22%
Chronic kidney disease 22%
Depression 20%
Atrial fibrillation 15%
COPD 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 33 51 $15,731

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $125
  • GENZYME CORPORATION $50
$175 22 —
Bimzelx
  • UCB, Inc. $91
$91 — —
TREMFYA
  • Janssen Biotech, Inc. $79
$79 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $67
$67 — —
Otezla
  • Amgen Inc. $60
$60 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

204 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record